FDA advisory panels to drop vote on approvability in favour of risk-benefit assessment
This article was originally published in Clinica
Executive Summary
The US Food and Drug Administration is to change to the way its medical device advisory committees discuss data and information during public hearings on products under review for premarket approval (PMA). The change will apply from 1 May.